+

WO1998011919A3 - Polyethyleneglycol conjugated nanoerythrosomes, method of making same and use thereof - Google Patents

Polyethyleneglycol conjugated nanoerythrosomes, method of making same and use thereof Download PDF

Info

Publication number
WO1998011919A3
WO1998011919A3 PCT/CA1997/000698 CA9700698W WO9811919A3 WO 1998011919 A3 WO1998011919 A3 WO 1998011919A3 CA 9700698 W CA9700698 W CA 9700698W WO 9811919 A3 WO9811919 A3 WO 9811919A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoerythrosomes
present
relates
making same
nanoerythrosome
Prior art date
Application number
PCT/CA1997/000698
Other languages
French (fr)
Other versions
WO1998011919A2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to CA002266388A priority Critical patent/CA2266388A1/en
Priority to AU43732/97A priority patent/AU4373297A/en
Priority to JP10514033A priority patent/JP2001501190A/en
Priority to EP97941755A priority patent/EP0929317A2/en
Publication of WO1998011919A2 publication Critical patent/WO1998011919A2/en
Publication of WO1998011919A3 publication Critical patent/WO1998011919A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to nanoErythrosomes, a Drug Delivery System (DDS). More specifically, the present invention relates to a new method of production of nanoErythrosomes. Moreover, the present invention relates to nanoErythrosome compositions having a decreased immunogenic potential and to the use thereof in diagnostic and therapeutic methods. The invention further relates to the bioassays using the nanoErythrosome composition of the present invention to diagnose or prognose a predetermined condition in an animal, as well as kits containing those nanoErythrosomes compositions.
PCT/CA1997/000698 1996-09-19 1997-09-19 Polyethyleneglycol conjugated nanoerythrosomes, method of making same and use thereof WO1998011919A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002266388A CA2266388A1 (en) 1996-09-19 1997-09-19 Polyethyleneglycol conjugated nanoerythrosomes, method of making same and use thereof
AU43732/97A AU4373297A (en) 1996-09-19 1997-09-19 Polyethyleneglycol conjugated nanoerythrosomes, method of making same and use thereof
JP10514033A JP2001501190A (en) 1996-09-19 1997-09-19 Polyethylene glycol conjugated nanoerythrosome, method for producing the same and use thereof
EP97941755A EP0929317A2 (en) 1996-09-19 1997-09-19 Polyethyleneglycol conjugated nanoerythrosomes, method of making same and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2636396P 1996-09-19 1996-09-19
US60/026,363 1996-09-19

Publications (2)

Publication Number Publication Date
WO1998011919A2 WO1998011919A2 (en) 1998-03-26
WO1998011919A3 true WO1998011919A3 (en) 1998-06-04

Family

ID=21831380

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CA1997/000698 WO1998011919A2 (en) 1996-09-19 1997-09-19 Polyethyleneglycol conjugated nanoerythrosomes, method of making same and use thereof
PCT/CA1997/000699 WO1998011920A2 (en) 1996-09-19 1997-09-19 Method of capture of a bioactive agent by a nanoerythrosome preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CA1997/000699 WO1998011920A2 (en) 1996-09-19 1997-09-19 Method of capture of a bioactive agent by a nanoerythrosome preparation

Country Status (5)

Country Link
EP (1) EP0929317A2 (en)
JP (1) JP2001501190A (en)
AU (2) AU4373397A (en)
CA (1) CA2266388A1 (en)
WO (2) WO1998011919A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10000838B4 (en) 2000-01-12 2005-03-17 Schott Ag Alkali-free aluminoborosilicate glass and its uses
EP1403639A1 (en) * 2002-09-30 2004-03-31 G2M Cancer Drugs AG Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
AU2003300133B2 (en) 2002-12-31 2008-11-13 Nektar Therapeutics Hydrolytically stable maleimide-terminated polymers
EP2015071A1 (en) * 2007-07-13 2009-01-14 FUJIFILM Corporation Carrier, process for producing same, bioreactor, and chip for surface plasmon resonance analysis
WO2011091154A2 (en) * 2010-01-21 2011-07-28 The Regents Of The University Of California Use of human erythrocytes for prevention and treatment of cancer dissemination and growth

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653999A (en) * 1995-02-07 1997-08-05 Universite Laval Nanoerythrosome as bioactive agent carrier

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653999A (en) * 1995-02-07 1997-08-05 Universite Laval Nanoerythrosome as bioactive agent carrier

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. KRANZ: "RED CELL-MEDIATED THERAPY: OPPORTUNITIES AND CHALLENGES.", BLOOD CELLS, MOLECULES, AND DISEASES, vol. 23, no. 3, 15 February 1997 (1997-02-15), pages 58 - 68, XP002060696 *
AM. J. HEMATOL. (1997), 56(1), 26-28 CODEN: AJHEDD;ISSN: 0361-8609, 1997 *
CHEMICAL ABSTRACTS, vol. 127, no. 22, 1 December 1997, Columbus, Ohio, US; abstract no. 305022, ARMSTRONG, JONATHAN K. ET AL: "Covalent binding of poly(ethylene glycol) (PEG) to the surface of red blood cells inhibits aggregation and reduces low shear blood viscosity" XP002060697 *
MOORJANI M. ET AL.: "PREPARATION AND USE OF NANO-ERYTHROSOMES AS A DRUG CARRIER FOR DAUNORUBICIN", PROC. ANN. MEET. AM. ASSOC. CANCER RES., vol. 35, March 1994 (1994-03-01), pages 415, XP002060694 *
V.R. MUZYKANTOV: "AVIDIN/BIOTIN-MEDIATED CONJUGATION OF ANTIBODIES TO ERYTHROCYTES: AN APPROACH FOR IN VIVO IMMUNOERYTHROCYTE EXPLORATION.", BIOMETHODS, vol. 7, 1996, pages 167 - 182, XP002060695 *

Also Published As

Publication number Publication date
EP0929317A2 (en) 1999-07-21
WO1998011919A2 (en) 1998-03-26
CA2266388A1 (en) 1998-03-26
WO1998011920A2 (en) 1998-03-26
JP2001501190A (en) 2001-01-30
AU4373297A (en) 1998-04-14
WO1998011920A3 (en) 1998-05-22
AU4373397A (en) 1998-04-14

Similar Documents

Publication Publication Date Title
CA2277824A1 (en) Dosage composition for nasal delivery and method of use of the same
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
AU4934496A (en) Method for in vitro preconditioning of myoblasts before transplantation
TR199900083T2 (en) Crystal form of clarithromycin I.
CA2230492A1 (en) Human growth hormone variants
EP0339237A3 (en) Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them
MX9703429A (en) Hemorrhoidal compositions and method of use.
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
IL142864A0 (en) Compositions and methods for producing vascular occlusion
DE69104991D1 (en) MOMETASON FUROATE MONOHYDRATE, METHOD FOR THE PRODUCTION THEREOF AND THE CONTAINING PHARMACEUTICAL COMPOSITIONS.
CA2336815A1 (en) Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
DE60018600D1 (en) BIOACTIVE COMPOUND COMPOSITE FOR "TISSUE ENGINEERING"
UA48946C2 (en) Arylalkyldiazinones, method for their preparation, pharmaceutical composition, method of its preparation and treatment method
ZA969820B (en) Fluorinated or hydroxylated phenylimidazolidines, preparation process and intermediates, use as medicaments, new use and pharmaceutical compositions.
NO902441D0 (en) Aroma delivery system, as well as chewing gum mixture.
MX9704030A (en) 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
CA2335551A1 (en) Thyroid hormone analogues and methods for their preparation
EP0388956A3 (en) Phthalinide derivative, pharmaceutical composition and use
EP0825197A3 (en) New 6-hydroxy and 6-oxo-anstro-stane derivatives active on the cardiovascular system and pharmaceutical compositions containing same
EP0136569A3 (en) Isoflavone derivatives, their production and use
WO1998011919A3 (en) Polyethyleneglycol conjugated nanoerythrosomes, method of making same and use thereof
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG102707A (en) New triazolopurinpurines, method for their preparation and appplication as medicamentous forms
AUPP823999A0 (en) A treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2266388

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2266388

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1998 514033

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997941755

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997941755

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1997941755

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载